<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Sun, 15 Oct 2023 10:08:53 +0000</lastbuilddate>
<pubDate>Sat, 14 Oct 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Residual lipidic risk beyond low-density lipoprotein cholesterol: new challenges and opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37837659/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 14;44(39):3935-3938. doi: 10.1093/eurheartj/ehad671.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37837659/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37837659</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad671>10.1093/eurheartj/ehad671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37837659</guid>
<pubDate>Sat, 14 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-10-14</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Residual lipidic risk beyond low-density lipoprotein cholesterol: new challenges and opportunities</dc:title>
<dc:identifier>pmid:37837659</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad671</dc:identifier>
</item>
<item>
<title>Metabolic reprogramming unlocks the regenerative potential of the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37833501/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 13. doi: 10.1038/s41569-023-00945-4. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37833501/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37833501</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00945-4>10.1038/s41569-023-00945-4</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37833501</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Metabolic reprogramming unlocks the regenerative potential of the heart</dc:title>
<dc:identifier>pmid:37833501</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00945-4</dc:identifier>
</item>
<item>
<title>Capturing and analysing the first vertebrate heartbeat</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37833500/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 13. doi: 10.1038/s41569-023-00944-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37833500/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37833500</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00944-5>10.1038/s41569-023-00944-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37833500</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Capturing and analysing the first vertebrate heartbeat</dc:title>
<dc:identifier>pmid:37833500</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00944-5</dc:identifier>
</item>
<item>
<title>Cytoplasmic division cycles without the nucleus and mitotic CDK/cyclin complexes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832525/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>Cytoplasmic divisions are thought to rely on nuclear divisions and mitotic signals. We demonstrate in Drosophila embryos that cytoplasm can divide repeatedly without nuclei and mitotic CDK/cyclin complexes. Cdk1 normally slows an otherwise faster cytoplasmic division cycle, coupling it with nuclear divisions, and when uncoupled, cytoplasm starts dividing before mitosis. In developing embryos where CDK/cyclin activity can license mitotic microtubule (MT) organizers like the spindle, cytoplasmic...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 12;186(21):4694-4709.e16. doi: 10.1016/j.cell.2023.09.010.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cytoplasmic divisions are thought to rely on nuclear divisions and mitotic signals. We demonstrate in Drosophila embryos that cytoplasm can divide repeatedly without nuclei and mitotic CDK/cyclin complexes. Cdk1 normally slows an otherwise faster cytoplasmic division cycle, coupling it with nuclear divisions, and when uncoupled, cytoplasm starts dividing before mitosis. In developing embryos where CDK/cyclin activity can license mitotic microtubule (MT) organizers like the spindle, cytoplasmic divisions can occur without the centrosome, a principal organizer of interphase MTs. However, centrosomes become essential in the absence of CDK/cyclin activity, implying that the cytoplasm can employ either the centrosome-based interphase or CDK/cyclin-dependent mitotic MTs to facilitate its divisions. Finally, we present evidence that autonomous cytoplasmic divisions occur during unperturbed fly embryogenesis and that they may help extrude mitotically stalled nuclei during blastoderm formation. We postulate that cytoplasmic divisions occur in cycles governed by a yet-to-be-uncovered clock mechanism autonomous from CDK/cyclin complexes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832525/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832525</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.010>10.1016/j.cell.2023.09.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832525</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anand Bakshi</dc:creator>
<dc:creator>Fabio Echegaray Iturra</dc:creator>
<dc:creator>Andrew Alamban</dc:creator>
<dc:creator>Miquel Rosas-Salvans</dc:creator>
<dc:creator>Sophie Dumont</dc:creator>
<dc:creator>Mustafa G Aydogan</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Cytoplasmic division cycles without the nucleus and mitotic CDK/cyclin complexes</dc:title>
<dc:identifier>pmid:37832525</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.010</dc:identifier>
</item>
<item>
<title>Deep discovery informs difficult deployment in plant microbiome science</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832524/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>Plant-associated microbiota can extend plant immune system function, improve nutrient acquisition and availability, and alleviate abiotic stresses. Thus, naturally beneficial microbial therapeutics are enticing tools to improve plant productivity. The basic definition of plant microbiota across species and ecosystems, combined with the development of reductionist experimental models and the manipulation of plant phenotypes with microbes, has fueled interest in its translation to agriculture....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 12;186(21):4496-4513. doi: 10.1016/j.cell.2023.08.035.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Plant-associated microbiota can extend plant immune system function, improve nutrient acquisition and availability, and alleviate abiotic stresses. Thus, naturally beneficial microbial therapeutics are enticing tools to improve plant productivity. The basic definition of plant microbiota across species and ecosystems, combined with the development of reductionist experimental models and the manipulation of plant phenotypes with microbes, has fueled interest in its translation to agriculture. However, the great majority of microbes exhibiting plant-productivity traits in the lab and greenhouse fail in the field. Therapeutic microbes must reach détente, the establishment of uneasy homeostasis, with the plant immune system, invade heterogeneous pre-established plant-associated communities, and persist in a new and potentially remodeled community. Environmental conditions can alter community structure and thus impact the engraftment of therapeutic microbes. We survey recent breakthroughs, challenges, and opportunities in translating beneficial microbes from the lab to the field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832524/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832524</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.035>10.1016/j.cell.2023.08.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832524</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dor Russ</dc:creator>
<dc:creator>Connor R Fitzpatrick</dc:creator>
<dc:creator>Paulo J P L Teixeira</dc:creator>
<dc:creator>Jeffery L Dangl</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Deep discovery informs difficult deployment in plant microbiome science</dc:title>
<dc:identifier>pmid:37832524</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.035</dc:identifier>
</item>
<item>
<title>ADP-ribosylation from molecular mechanisms to therapeutic implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832523/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>ADP-ribosylation is a ubiquitous modification of biomolecules, including proteins and nucleic acids, that regulates various cellular functions in all kingdoms of life. The recent emergence of new technologies to study ADP-ribosylation has reshaped our understanding of the molecular mechanisms that govern the establishment, removal, and recognition of this modification, as well as its impact on cellular and organismal function. These advances have also revealed the intricate involvement of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 12;186(21):4475-4495. doi: 10.1016/j.cell.2023.08.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">ADP-ribosylation is a ubiquitous modification of biomolecules, including proteins and nucleic acids, that regulates various cellular functions in all kingdoms of life. The recent emergence of new technologies to study ADP-ribosylation has reshaped our understanding of the molecular mechanisms that govern the establishment, removal, and recognition of this modification, as well as its impact on cellular and organismal function. These advances have also revealed the intricate involvement of ADP-ribosylation in human physiology and pathology and the enormous potential that their manipulation holds for therapy. In this review, we present the state-of-the-art findings covering the work in structural biology, biochemistry, cell biology, and clinical aspects of ADP-ribosylation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832523/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832523</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.030>10.1016/j.cell.2023.08.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832523</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Marcin J Suskiewicz</dc:creator>
<dc:creator>Evgeniia Prokhorova</dc:creator>
<dc:creator>Johannes G M Rack</dc:creator>
<dc:creator>Ivan Ahel</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Cell</dc:source>
<dc:title>ADP-ribosylation from molecular mechanisms to therapeutic implications</dc:title>
<dc:identifier>pmid:37832523</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.030</dc:identifier>
</item>
<item>
<title>Actionable autophagy checkpoints in cardiovascular ageing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 13:ehad661. doi: 10.1093/eurheartj/ehad661. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832515</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad661>10.1093/eurheartj/ehad661</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832515</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Mahmoud Abdellatif</dc:creator>
<dc:creator>Léa Montégut</dc:creator>
<dc:creator>Guido Kroemer</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Actionable autophagy checkpoints in cardiovascular ageing</dc:title>
<dc:identifier>pmid:37832515</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad661</dc:identifier>
</item>
<item>
<title>Intra-pocket ultrasound-guided axillary vein puncture vs. cephalic vein cutdown for cardiac electronic device implantation: the ACCESS trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: IPUS-AVP is superior to CVC in terms of success rate, time to venous access, procedure duration, and radiation exposure. Complication rates were similar between the two groups. Intra-pocket ultrasound-guided axillary vein puncture should be a recommended venous access technique for CIED implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 13:ehad629. doi: 10.1093/eurheartj/ehad629. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Intra-pocket ultrasound-guided axillary vein puncture (IPUS-AVP) for venous access in implantation of transvenous cardiac implantable electronic devices (CIED) is uncommon due to the lack of clinical evidence supporting this technique. This study investigated the efficacy and early complications of IPUS-AVP compared to the standard method using cephalic vein cutdown (CVC) for CIED implantation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: ACCESS was an investigator-led, interventional, randomized (1:1 ratio), monocentric, controlled superiority trial. A total of 200 patients undergoing CIED implantation were randomized to IPUS-AVP (n = 101) or CVC (n = 99) as a first assigned route. The primary endpoint was the success rate of insertion of all leads using the first assigned venous access technique. The secondary endpoints were time to venous access, total procedure duration, fluoroscopy time, X-ray exposure, and complications. Complications were monitored during a follow-up period of three months after procedure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: IPUS-AVP was significantly superior to CVC for the primary endpoint with 100 (99.0%) vs. 86 (86.9%) procedural successes (P = .001). Cephalic vein cutdown followed by subclavian vein puncture was successful in a total of 95 (96.0%) patients, P = .21 vs. IPUS-AVP. All secondary endpoints were also significantly improved in the IPUS-AVP group with reduction in time to venous access [3.4 vs. 10.6 min, geometric mean ratio (GMR) 0.32 (95% confidence interval, CI, 0.28-0.36), P &lt; .001], total procedure duration [33.8 vs. 46.9 min, GMR 0.72 (95% CI 0.67-0.78), P &lt; .001], fluoroscopy time [2.4 vs. 3.3 min, GMR 0.74 (95% CI 0.63-0.86), P &lt; .001], and X-ray exposure [1083 vs. 1423 mGy.cm², GMR 0.76 (95% CI 0.62-0.93), P = .009]. There was no significant difference in complication rates between groups (P = .68).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: IPUS-AVP is superior to CVC in terms of success rate, time to venous access, procedure duration, and radiation exposure. Complication rates were similar between the two groups. Intra-pocket ultrasound-guided axillary vein puncture should be a recommended venous access technique for CIED implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832512</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad629>10.1093/eurheartj/ehad629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832512</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Paul Charles</dc:creator>
<dc:creator>Geoffroy Ditac</dc:creator>
<dc:creator>Mathieu Montoy</dc:creator>
<dc:creator>Thibaut Thenard</dc:creator>
<dc:creator>Pierre-Yves Courand</dc:creator>
<dc:creator>Pierre Lantelme</dc:creator>
<dc:creator>Brahim Harbaoui</dc:creator>
<dc:creator>Samir Fareh</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intra-pocket ultrasound-guided axillary vein puncture vs. cephalic vein cutdown for cardiac electronic device implantation: the ACCESS trial</dc:title>
<dc:identifier>pmid:37832512</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad629</dc:identifier>
</item>
<item>
<title>Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37832033/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 13:ehad669. doi: 10.1093/eurheartj/ehad669. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37832033/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37832033</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad669>10.1093/eurheartj/ehad669</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37832033</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Dinesh Shrikrishna</dc:creator>
<dc:creator>Clare J Taylor</dc:creator>
<dc:creator>Carol Stonham</dc:creator>
<dc:creator>Chris P Gale</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Exacerbating the burden of cardiovascular disease: how can we address cardiopulmonary risk in individuals with chronic obstructive pulmonary disease?</dc:title>
<dc:identifier>pmid:37832033</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad669</dc:identifier>
</item>
<item>
<title>Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37830218/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In patients with CHF who have received CRT, diastolic stepping increases stroke volume and oxygen delivery and decreases afterload. We speculate that, if added to pacemakers, this cardio-locomotor coupling technology may maximize CRT efficiency and increase exercise participation and quality of life in patients with CHF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite advances in medical and cardiac resynchronization therapy (CRT), individuals with chronic congestive heart failure (CHF) have persistent symptoms, including exercise intolerance. Optimizing cardio-locomotor coupling may increase stroke volume and skeletal muscle perfusion as previously shown in healthy runners. Therefore, we tested the hypothesis that exercise stroke volume and cardiac output would be higher during fixed-paced walking when steps were synchronized with the diastolic compared with systolic portion of the cardiac cycle in patients with CHF and CRT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Ten participants (58±17 years of age; 40% female) with CHF and previously implanted CRT pacemakers completed 5-minute bouts of walking on a treadmill (range, 1.5-3 mph). Participants were randomly assigned to walking to an auditory tone to synchronize their foot strike to either the systolic (0% or 100±15% of the R-R interval) or diastolic phase (45±15% of the R-R interval) of their cardiac cycle and underwent assessments of oxygen uptake (V̇o<sub>2</sub>; indirect calorimetry) and cardiac output (acetylene rebreathing). Data were compared through paired-samples <i>t</i> tests.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: V̇o<sub>2</sub> was similar between conditions (diastolic 1.02±0.44 versus systolic 1.05±0.42 L/min; <i>P</i>=0.299). Compared with systolic walking, stroke volume (diastolic 80±28 versus systolic 74±26 mL; <i>P</i>=0.003) and cardiac output (8.3±3.5 versus 7.9±3.4 L/min; <i>P</i>=0.004) were higher during diastolic walking; heart rate (paced) was not different between conditions. Mean arterial pressure was significantly lower during diastolic walking (85±12 versus 98±20 mm Hg; <i>P</i>=0.007).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients with CHF who have received CRT, diastolic stepping increases stroke volume and oxygen delivery and decreases afterload. We speculate that, if added to pacemakers, this cardio-locomotor coupling technology may maximize CRT efficiency and increase exercise participation and quality of life in patients with CHF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37830218/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37830218</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066170>10.1161/CIRCULATIONAHA.123.066170</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37830218</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Denis J Wakeham</dc:creator>
<dc:creator>Erika Ivey</dc:creator>
<dc:creator>Sophie Saland</dc:creator>
<dc:creator>Joshua Lewis</dc:creator>
<dc:creator>Dean Palmer</dc:creator>
<dc:creator>Margot Morris</dc:creator>
<dc:creator>Jeffery L Bleich</dc:creator>
<dc:creator>Peter G Weyand</dc:creator>
<dc:creator>Tiffany L Brazile</dc:creator>
<dc:creator>Christopher M Hearon</dc:creator>
<dc:creator>Satyam Sarma</dc:creator>
<dc:creator>James P MacNamara</dc:creator>
<dc:creator>Michinari Hieda</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure</dc:title>
<dc:identifier>pmid:37830218</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066170</dc:identifier>
</item>
<item>
<title>Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37830208/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: aTRH was identified in >;1 in 10 patients with heart failure and left ventricular ejection fraction >;40% in DELIVER. Dapagliflozin consistently improved clinical outcomes and was well-tolerated, including among those with aTRH.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population. In this post hoc analysis of the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure), we evaluated clinical profiles and treatment effects of dapagliflozin among participants with aTRH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: DELIVER participants were categorized on the basis of baseline blood pressure (BP), with aTRH defined as BP ≥140/90 mm Hg (≥130/80 mm Hg if diabetes) despite treatment with 3 antihypertensive drugs including a diuretic. Nonresistant hypertension was defined as BP above threshold but not meeting aTRH criteria. Controlled BP was defined as BP under threshold. Incidence of the primary outcome (cardiovascular death or worsening heart failure event), key secondary outcomes, and safety events was assessed by baseline BP category.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 6263 DELIVER participants, 3766 (60.1%) had controlled BP, 1779 (28.4%) had nonresistant hypertension, and 718 (11.5%) had aTRH at baseline. Participants with aTRH had more cardiometabolic comorbidities and tended to have higher left ventricular ejection fraction and worse kidney function. Rates of the primary outcome were 8.7 per 100 patient-years in those with controlled BP, 8.5 per 100 patient-years in the nonresistant hypertension group, and 9.5 per 100 patient-years in the aTRH group. Relative treatment benefits of dapagliflozin versus placebo on the primary outcome were consistent across BP categories (<i>P</i><sub>interaction</sub>=0.114). Participants with aTRH exhibited the greatest absolute reduction in the rate of primary events with dapagliflozin (4.1 per 100 patient-years) compared with nonresistant hypertension (2.7 per 100 patient-years) and controlled BP (0.8 per 100 patient-years). Irrespective of assigned treatment, participants with aTRH experienced a higher rate of reported vascular events, including myocardial infarction and stroke, over study follow-up. Dapagliflozin modestly reduced systolic BP (by ≈1 to 3 mm Hg) without increasing risk of hypotension, hypovolemia, or other serious adverse events, irrespective of BP category, but did not improve the proportion of participants with aTRH attaining goal BP over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: aTRH was identified in >;1 in 10 patients with heart failure and left ventricular ejection fraction >;40% in DELIVER. Dapagliflozin consistently improved clinical outcomes and was well-tolerated, including among those with aTRH.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT03619213.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37830208/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37830208</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065254>10.1161/CIRCULATIONAHA.123.065254</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37830208</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>John W Ostrominski</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Senthil Selvaraj</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Zi Michael Miao</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Felipe A Martinez</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Magnus Petersson</dc:creator>
<dc:creator>Anna Maria Langkilde</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial</dc:title>
<dc:identifier>pmid:37830208</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065254</dc:identifier>
</item>
<item>
<title>Comparative Discrimination of Life's Simple 7 and Life's Essential 8 to Stratify Cardiovascular Risk: Is the Added Complexity Worth It?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37830200/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Both LS7 and LE8 were associated with incident CVD, with discrimination of the 2 indices practically indistinguishable. As a simpler metric, LS7 may be favored for use by the general population and clinicians.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065472. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Life's Simple 7 (LS7) is an easily calculated and interpreted metric of cardiovascular health based on 7 domains: smoking, diet, physical activity, body mass index, blood pressure, cholesterol, and fasting glucose. The Life's Essential 8 (LE8) metric was subsequently introduced, adding sleep metrics and revisions of the previous 7 domains. Although calculating LE8 requires additional information, we hypothesized that it would be a more reliable index of cardiovascular health.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Both the LS7 and LE8 metrics yield scores with higher values indicating lower risk. These were calculated among 11 609 Black and White participants free of baseline cardiovascular disease (CVD) in the Reasons for Geographic and Racial Differences in Stroke study, enrolled in 2003 to 2007, and followed for a median of 13 years. Differences in 10-year risk of incident CVD (coronary heart disease or stroke) were calculated as a function LS7, and LE8 scores were calculated using Kaplan-Meier and proportional hazards analyses. Differences in incident CVD discrimination were quantified by difference in the c-statistic.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For both LS7 and LE8, the 10-year risk was approximately 5% for participants around the 99th percentile of scores, and a 4× higher 20% risk for participants around the first percentile. Comparing LS7 to LE8, 10-year risk was nearly identical for individuals at the same relative position in score distribution. For example, the "cluster" of 2013 participants with an LS7 score of 7 was at the 35.8th percentile in distribution of LS7 scores, and had an estimated 10-year CVD risk of 8.4% (95% CI, 7.2%-9.8%). In a similar location in the LE8 distribution, the 1457 participants with an LE8 score of 60±2.5 at the 39.4th percentile of LE8 scores, with a 10-year risk of CVD of 8.5% (95% CI, 7.1%-10.1%), similar to the cluster defined by LS7. The age-race-sex adjusted c-statistic of the LS7 model was 0.691 (95% CI, 0.667-0.705), and 0.695 for LE8 (95% CI, 0.681-0.709) (<i>P</i> for difference, 0.12).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Both LS7 and LE8 were associated with incident CVD, with discrimination of the 2 indices practically indistinguishable. As a simpler metric, LS7 may be favored for use by the general population and clinicians.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37830200/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37830200</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065472>10.1161/CIRCULATIONAHA.123.065472</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37830200</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>George Howard</dc:creator>
<dc:creator>Mary Cushman</dc:creator>
<dc:creator>Jessica Blair</dc:creator>
<dc:creator>Nicole R Wilson</dc:creator>
<dc:creator>Ya Yuan</dc:creator>
<dc:creator>Monika M Safford</dc:creator>
<dc:creator>Emily B Levitan</dc:creator>
<dc:creator>Suzanne E Judd</dc:creator>
<dc:creator>Virginia J Howard</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Comparative Discrimination of Life's Simple 7 and Life's Essential 8 to Stratify Cardiovascular Risk: Is the Added Complexity Worth It?</dc:title>
<dc:identifier>pmid:37830200</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065472</dc:identifier>
</item>
<item>
<title>Asymptomatic Patients With Brugada ECG Pattern: Long-Term Prognosis From a Large Prospective Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37830188/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: The entire population of asymptomatic patients with BrECG exhibits a relatively low event rate per year, which is important in view of the long life expectancy of these young patients. The presence of spontaneous type-1 BrECG associated with positive EPS identifies a subgroup at higher risk. Asymptomatic patients with drug-induced-only BrECG have a minimal arrhythmic risk, but ongoing follow-up with 12-lead Holter monitoring is recommended to detect the appearance of spontaneous...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.064689. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Brugada syndrome poses significant challenges in terms of risk stratification and management, particularly for asymptomatic patients who comprise the majority of individuals exhibiting Brugada pattern ECG (BrECG). The aim of this study was to evaluate the long-term prognosis of a large cohort of asymptomatic patients with BrECG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Asymptomatic patients with BrECG (1149) were consecutively collected from 2 Italian centers and followed-up at least annually for 2 to 22 years. For the 539 asymptomatic patients (men, 433 [80%]; mean age, 46±13 years) with spontaneous type 1 documented on baseline ECG (87%) or 12-lead 24-hour Holter monitoring (13%), an electrophysiologic study (EPS) was proposed; for the 610 patients with drug-induced-only type 1 (men, 420 [69%]; mean age, 44±14 years), multiple ECGs and 12-lead Holter were advised in order to detect the occurrence of a spontaneous type-1 BrECG pattern. Arrhythmic events were defined as sudden death or documented ventricular fibrillation or tachycardia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Median follow-up was 6 (4-9) years. Seventeen (1.5%) arrhythmic events occurred in the overall asymptomatic population (corresponding to an event-rate of 0.2% per year), including 16 of 539 (0.4% per year) in patients with spontaneous type-1 BrECG and 1 of 610 in those with drug-induced type-1 BrECG (0.03% per year; <i>P</i>&lt;0.001). EPS was performed in 339 (63%) patients with spontaneous type-1 BrECG. Patients with spontaneous type-1 BrECG and positive EPS had significantly higher event rates than patients with negative EPS (7 of 103 [0.7% per year] versus 4 of 236 [0.2% per year]; <i>P</i>=0.025). Among 200 patients who declined EPS, 5 events (0.4% per year) occurred. There was 1 device-related death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The entire population of asymptomatic patients with BrECG exhibits a relatively low event rate per year, which is important in view of the long life expectancy of these young patients. The presence of spontaneous type-1 BrECG associated with positive EPS identifies a subgroup at higher risk. Asymptomatic patients with drug-induced-only BrECG have a minimal arrhythmic risk, but ongoing follow-up with 12-lead Holter monitoring is recommended to detect the appearance of spontaneous type-1 BrECG pattern.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37830188/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37830188</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064689>10.1161/CIRCULATIONAHA.123.064689</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37830188</guid>
<pubDate>Fri, 13 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Fiorenzo Gaita</dc:creator>
<dc:creator>Natascia Cerrato</dc:creator>
<dc:creator>Carla Giustetto</dc:creator>
<dc:creator>Annamaria Martino</dc:creator>
<dc:creator>Laura Bergamasco</dc:creator>
<dc:creator>Michele Millesimo</dc:creator>
<dc:creator>Lorella Barbonaglia</dc:creator>
<dc:creator>Paula Carvalho</dc:creator>
<dc:creator>Domenico Caponi</dc:creator>
<dc:creator>Andrea Saglietto</dc:creator>
<dc:creator>Giacomo Bonacchi</dc:creator>
<dc:creator>Francesca Bianchi</dc:creator>
<dc:creator>Elisa Silvetti</dc:creator>
<dc:creator>Cinzia Crescenzi</dc:creator>
<dc:creator>Stefano Canestrelli</dc:creator>
<dc:creator>Melissa De Maio</dc:creator>
<dc:creator>Gaetano Maria De Ferrari</dc:creator>
<dc:creator>Giuseppe Musumeci</dc:creator>
<dc:creator>Francesco Rametta</dc:creator>
<dc:creator>Marco Scaglione</dc:creator>
<dc:creator>Leonardo Calò</dc:creator>
<dc:date>2023-10-13</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Asymptomatic Patients With Brugada ECG Pattern: Long-Term Prognosis From a Large Prospective Study</dc:title>
<dc:identifier>pmid:37830188</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064689</dc:identifier>
</item>
<item>
<title>Antagonistic roles of canonical and Alternative-RPA in disease-associated tandem CAG repeat instability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37827155/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>Expansions of repeat DNA tracts cause >;70 diseases, and ongoing expansions in brains exacerbate disease. During expansion mutations, single-stranded DNAs (ssDNAs) form slipped-DNAs. We find the ssDNA-binding complexes canonical replication protein A (RPA1, RPA2, and RPA3) and Alternative-RPA (RPA1, RPA3, and primate-specific RPA4) are upregulated in Huntington disease and spinocerebellar ataxia type 1 (SCA1) patient brains. Protein interactomes of RPA and Alt-RPA reveal unique and shared...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 5:S0092-8674(23)01030-9. doi: 10.1016/j.cell.2023.09.008. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Expansions of repeat DNA tracts cause >;70 diseases, and ongoing expansions in brains exacerbate disease. During expansion mutations, single-stranded DNAs (ssDNAs) form slipped-DNAs. We find the ssDNA-binding complexes canonical replication protein A (RPA1, RPA2, and RPA3) and Alternative-RPA (RPA1, RPA3, and primate-specific RPA4) are upregulated in Huntington disease and spinocerebellar ataxia type 1 (SCA1) patient brains. Protein interactomes of RPA and Alt-RPA reveal unique and shared partners, including modifiers of CAG instability and disease presentation. RPA enhances in vitro melting, FAN1 excision, and repair of slipped-CAGs and protects against CAG expansions in human cells. RPA overexpression in SCA1 mouse brains ablates expansions, coincident with decreased ATXN1 aggregation, reduced brain DNA damage, improved neuron morphology, and rescued motor phenotypes. In contrast, Alt-RPA inhibits melting, FAN1 excision, and repair of slipped-CAGs and promotes CAG expansions. These findings suggest a functional interplay between the two RPAs where Alt-RPA may antagonistically offset RPA's suppression of disease-associated repeat expansions, which may extend to other DNA processes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37827155/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37827155</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.09.008>10.1016/j.cell.2023.09.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37827155</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Terence Gall-Duncan</dc:creator>
<dc:creator>Jennifer Luo</dc:creator>
<dc:creator>Carla-Marie Jurkovic</dc:creator>
<dc:creator>Laura A Fischer</dc:creator>
<dc:creator>Kyota Fujita</dc:creator>
<dc:creator>Amit L Deshmukh</dc:creator>
<dc:creator>Rachel J Harding</dc:creator>
<dc:creator>Stephanie Tran</dc:creator>
<dc:creator>Mustafa Mehkary</dc:creator>
<dc:creator>Vanessa Li</dc:creator>
<dc:creator>David E Leib</dc:creator>
<dc:creator>Ran Chen</dc:creator>
<dc:creator>Hikari Tanaka</dc:creator>
<dc:creator>Amanda G Mason</dc:creator>
<dc:creator>Dominique Lévesque</dc:creator>
<dc:creator>Mahreen Khan</dc:creator>
<dc:creator>Mortezaali Razzaghi</dc:creator>
<dc:creator>Tanya Prasolava</dc:creator>
<dc:creator>Stella Lanni</dc:creator>
<dc:creator>Nozomu Sato</dc:creator>
<dc:creator>Marie-Christine Caron</dc:creator>
<dc:creator>Gagan B Panigrahi</dc:creator>
<dc:creator>Peixiang Wang</dc:creator>
<dc:creator>Rachel Lau</dc:creator>
<dc:creator>Arturo López Castel</dc:creator>
<dc:creator>Jean-Yves Masson</dc:creator>
<dc:creator>Lynette Tippett</dc:creator>
<dc:creator>Clinton Turner</dc:creator>
<dc:creator>Maria Spies</dc:creator>
<dc:creator>Albert R La Spada</dc:creator>
<dc:creator>Eric I Campos</dc:creator>
<dc:creator>Maurice A Curtis</dc:creator>
<dc:creator>François-Michel Boisvert</dc:creator>
<dc:creator>Richard L M Faull</dc:creator>
<dc:creator>Beverly L Davidson</dc:creator>
<dc:creator>Masayuki Nakamori</dc:creator>
<dc:creator>Hitoshi Okazawa</dc:creator>
<dc:creator>Marc S Wold</dc:creator>
<dc:creator>Christopher E Pearson</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Antagonistic roles of canonical and Alternative-RPA in disease-associated tandem CAG repeat instability</dc:title>
<dc:identifier>pmid:37827155</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.09.008</dc:identifier>
</item>
<item>
<title>Does Obesity Explain Cardiovascular Risk due to Adverse Pregnancy Outcomes?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37824605/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 13;133(9):736-738. doi: 10.1161/CIRCRESAHA.123.323540. Epub 2023 Oct 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37824605/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37824605</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323540>10.1161/CIRCRESAHA.123.323540</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37824605</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Anum S Minhas</dc:creator>
<dc:creator>Theresa Boyer</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Does Obesity Explain Cardiovascular Risk due to Adverse Pregnancy Outcomes?</dc:title>
<dc:identifier>pmid:37824605</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323540</dc:identifier>
</item>
<item>
<title>Correction to: Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37824604/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 13;133(9):e50. doi: 10.1161/RES.0000000000000636. Epub 2023 Oct 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37824604/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37824604</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000636>10.1161/RES.0000000000000636</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37824604</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Frataxin Deacetylation in Macrophages: Avoiding SIRTain Myocyte Death</dc:title>
<dc:identifier>pmid:37824604</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000636</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37824602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 13;133(9):724. doi: 10.1161/RES.0000000000000639. Epub 2023 Oct 12.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37824602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37824602</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000639>10.1161/RES.0000000000000639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37824602</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37824602</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000639</dc:identifier>
</item>
<item>
<title>Disrupted Functional Brain Connectome in the Fetus With Congenital Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37823309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 12. doi: 10.1161/CIRCRESAHA.123.323276. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37823309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37823309</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323276>10.1161/CIRCRESAHA.123.323276</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37823309</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Josepheen De Asis-Cruz</dc:creator>
<dc:creator>Nickie Andescavage</dc:creator>
<dc:creator>Mary T Donofrio</dc:creator>
<dc:creator>Gilbert Vezina</dc:creator>
<dc:creator>David Wessel</dc:creator>
<dc:creator>Adre du Plessis</dc:creator>
<dc:creator>Catherine Limperopoulos</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Disrupted Functional Brain Connectome in the Fetus With Congenital Heart Disease</dc:title>
<dc:identifier>pmid:37823309</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323276</dc:identifier>
</item>
<item>
<title>Single-Nuclei RNA-Sequencing of the Gastrocnemius Muscle in Peripheral Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37823262/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: This reference single-nuclei RNA-sequencing atlas provides a comprehensive analysis of the cell composition, transcriptional signature, and intercellular communication pathways that are altered in the PAD condition.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Oct 12. doi: 10.1161/CIRCRESAHA.123.323161. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Lower extremity peripheral artery disease (PAD) is a growing epidemic with limited effective treatment options. Here, we provide a single-nuclei atlas of PAD limb muscle to facilitate a better understanding of the composition of cells and transcriptional differences that comprise the diseased limb muscle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We obtained gastrocnemius muscle specimens from 20 patients with PAD and 12 non-PAD controls. Nuclei were isolated and single-nuclei RNA-sequencing was performed. The composition of nuclei was characterized by iterative clustering via principal component analysis, differential expression analysis, and the use of known marker genes. Bioinformatics analysis was performed to determine differences in gene expression between PAD and non-PAD nuclei, as well as subsequent analysis of intercellular signaling networks. Additional histological analyses of muscle specimens accompany the single-nuclei RNA-sequencing atlas.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Single-nuclei RNA-sequencing analysis indicated a fiber type shift with patients with PAD having fewer type I (slow/oxidative) and more type II (fast/glycolytic) myonuclei compared with non-PAD, which was confirmed using immunostaining of muscle specimens. Myonuclei from PAD displayed global upregulation of genes involved in stress response, autophagy, hypoxia, and atrophy. Subclustering of myonuclei also identified populations that were unique to PAD muscle characterized by metabolic dysregulation. PAD muscles also displayed unique transcriptional profiles and increased diversity of transcriptomes in muscle stem cells, regenerating myonuclei, and fibro-adipogenic progenitor cells. Analysis of intercellular communication networks revealed fibro-adipogenic progenitors as a major signaling hub in PAD muscle, as well as deficiencies in angiogenic and bone morphogenetic protein signaling which may contribute to poor limb function in PAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This reference single-nuclei RNA-sequencing atlas provides a comprehensive analysis of the cell composition, transcriptional signature, and intercellular communication pathways that are altered in the PAD condition.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37823262/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37823262</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323161>10.1161/CIRCRESAHA.123.323161</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37823262</guid>
<pubDate>Thu, 12 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Caroline Pass</dc:creator>
<dc:creator>Victoria Palzkill</dc:creator>
<dc:creator>Jianna Tan</dc:creator>
<dc:creator>Kyoungrae Kim</dc:creator>
<dc:creator>Trace Thome</dc:creator>
<dc:creator>Qingping Yang</dc:creator>
<dc:creator>Brian Fazzone</dc:creator>
<dc:creator>Scott T Robinson</dc:creator>
<dc:creator>Kerri A O'Malley</dc:creator>
<dc:creator>Feng Yue</dc:creator>
<dc:creator>Salvatore T Scali</dc:creator>
<dc:creator>Scott A Berceli</dc:creator>
<dc:creator>Terence E Ryan</dc:creator>
<dc:date>2023-10-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Single-Nuclei RNA-Sequencing of the Gastrocnemius Muscle in Peripheral Artery Disease</dc:title>
<dc:identifier>pmid:37823262</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323161</dc:identifier>
</item>
<item>
<title>Acute coronary syndromes: new guidelines and new light shed on biomarkers and mechanisms of plaque instability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37822014/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 12;44(38):3707-3711. doi: 10.1093/eurheartj/ehad656.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37822014/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37822014</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad656>10.1093/eurheartj/ehad656</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37822014</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acute coronary syndromes: new guidelines and new light shed on biomarkers and mechanisms of plaque instability</dc:title>
<dc:identifier>pmid:37822014</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad656</dc:identifier>
</item>
<item>
<title>Socioeconomic inequalities in cardiovascular disease: a causal perspective</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37821646/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231015060852&amp;v=2.17.9.post6+86293ac
      <description>Socioeconomic inequalities in cardiovascular disease (CVD) persist in high-income countries despite marked overall declines in CVD-related morbidity and mortality. After decades of research, the field has struggled to unequivocally answer a crucial question: is the association between low socioeconomic position (SEP) and the development of CVD causal? We review relevant evidence from various study designs and disciplinary perspectives. Traditional observational, family-based and Mendelian...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Oct 11. doi: 10.1038/s41569-023-00941-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Socioeconomic inequalities in cardiovascular disease (CVD) persist in high-income countries despite marked overall declines in CVD-related morbidity and mortality. After decades of research, the field has struggled to unequivocally answer a crucial question: is the association between low socioeconomic position (SEP) and the development of CVD causal? We review relevant evidence from various study designs and disciplinary perspectives. Traditional observational, family-based and Mendelian randomization studies support the widely accepted view that low SEP causally influences CVD. However, results from quasi-experimental and experimental studies are both limited and equivocal. While more experimental and quasi-experimental studies are needed to aid causal understanding and inform policy, high-quality descriptive studies are also required to document inequalities, investigate their contextual dependence and consider SEP throughout the lifespan; no simple hierarchy of evidence exists for an exposure as complex as SEP. The COVID-19 pandemic illustrates the context-dependent nature of CVD inequalities, with the generation of potentially new causal pathways linking SEP and CVD. The linked goals of understanding the causal nature of SEP and CVD associations, their contextual dependence, and their remediation by policy interventions necessitate a detailed understanding of society, its change over time and the phenotypes of CVD. Interdisciplinary research is therefore key to advancing both causal understanding and policy translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37821646/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231015060852&v=2.17.9.post6+86293ac">37821646</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00941-8>10.1038/s41569-023-00941-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37821646</guid>
<pubDate>Wed, 11 Oct 2023 06:00:00 -0400</pubDate>
<dc:creator>David Bann</dc:creator>
<dc:creator>Liam Wright</dc:creator>
<dc:creator>Alun Hughes</dc:creator>
<dc:creator>Nish Chaturvedi</dc:creator>
<dc:date>2023-10-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Socioeconomic inequalities in cardiovascular disease: a causal perspective</dc:title>
<dc:identifier>pmid:37821646</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00941-8</dc:identifier>
</item>





























</channel>
</rss>